Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13662Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chitkara, Deepak | - |
| dc.contributor.author | Mittal, Anupama | - |
| dc.date.accessioned | 2024-01-04T10:34:39Z | - |
| dc.date.available | 2024-01-04T10:34:39Z | - |
| dc.date.issued | 2019-04 | - |
| dc.identifier.uri | https://www.future-science.com/doi/abs/10.4155/tde-2018-0074 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13662 | - |
| dc.description.abstract | The current study aims to co-deliver docetaxel (DTX) and alpha-lipoic acid (ALA) using solid lipid nanoparticles (SLNs) as a carrier for the treatment of breast cancer. Methods: Computational analysis was used to screen different solid lipids as carriers, following which SLNs were prepared and characterized. Furthermore, antioxidant activity assays and cell culture studies were performed. Results:In vitro assessment in 4T1 (murine mammary carcinoma) and MCF-7 (human breast adenocarcinoma) cells revealed enhanced efficacy of the co-loaded SLNs as compared with free drugs and single drug-loaded SLNs. Increased apoptosis following treatment with DTX-ALA co-loaded SLN was also observed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Future Science Group | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Breast cancer | en_US |
| dc.subject | Solid lipid nanoparticles (SLNs) | en_US |
| dc.subject | Cellular uptake | en_US |
| dc.title | Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.